The advent of direct-acting antivirals (DAAs) has brought about a sudden renaissance in the
treatment of chronic hepatitis C virus (HCV) infection with SVR rates now routinely> 90 …

Emerging viruses are a major threat to human health. Recent outbreaks have emphasized
the urgent need for new antiviral treatments. For several pathogenic viruses, considerable …

Members of the Flaviviridae family are posing a significant threat to human health
worldwide. Many flaviviruses are capable of inducing severe inflammation in humans …

Multiple direct-acting antiviral (DAA)-based regimens are currently approved that provide
one or more interferon-free treatment options for hepatitis C virus (HCV) genotypes (G) 1–6 …

Hepatitis C virus (HCV) preferentially replicates in the human liver and frequently causes
chronic infection, often leading to cirrhosis and liver cancer. HCV is an enveloped virus …

Background: The hepatitis C virus has a high mutation rate, which results in the emergence
of resistance-associated substitutions (RASs). Despite direct-acting antivirals (DAAs) efforts …

Plus-strand RNA viruses are the largest group of viruses. Many are human pathogens that
inflict a socio-economic burden. Interestingly, plus-strand RNA viruses share remarkable …

Background Despite the high sustained virological response rates achieved with current
directly-acting antiviral agents (DAAs) against hepatitis C virus (HCV), around 5–10% of …

The use of direct-acting antivirals (DAAs) to treat chronic hepatitis C has resulted in a
significant increase in rates of sustained viral response (around 90%-95%) as compared …

Sofosbuvir displays a high phenotypic barrier to resistance, and it is a component of several
combination therapies for hepatitis C virus (HCV) infections. HCV fitness can be a …